{"id":63749,"date":"2026-04-22T22:33:02","date_gmt":"2026-04-22T14:33:02","guid":{"rendered":"https:\/\/flcube.com\/?p=63749"},"modified":"2026-04-22T22:33:03","modified_gmt":"2026-04-22T14:33:03","slug":"boji-medical-sells-fluconazole-ear-drops-technology-to-chengdu-pusch-for-2m","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63749","title":{"rendered":"Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M"},"content":{"rendered":"\n

Boji Medical Technology Co., Ltd.<\/strong> (SHE: 300404<\/a>), a Chinese clinical research organization (CRO), has entered into a technology transfer agreement<\/strong> with fellow domestic pharmaceutical company Chengdu Pusch Pharmaceutical Co., Ltd.<\/strong>, transferring its fluconazole ear drops<\/strong> formulation for RMB 14 million (USD 2 million)<\/strong>.<\/p>\n\n\n\n

Transaction Details<\/h2>\n\n\n\n
Attribute<\/th>Detail<\/th><\/tr><\/thead>
Seller<\/strong><\/td>Boji Medical Technology Co., Ltd. (SHE: 300404)<\/td><\/tr>
Buyer<\/strong><\/td>Chengdu Pusch Pharmaceutical Co., Ltd.<\/td><\/tr>
Asset<\/strong><\/td>Fluconazole ear drops (Category 2.2\/2.4 drug)<\/td><\/tr>
Indication<\/strong><\/td>External otitis caused by fungal infections<\/td><\/tr>
Development Stage<\/strong><\/td>Pre-clinical trials completed<\/td><\/tr>
Transaction Value<\/strong><\/td>RMB 14 million (USD 2 million)<\/td><\/tr>
Transaction Type<\/strong><\/td>Technology transfer agreement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The transferred asset represents a reformulation of the established antifungal agent fluconazole for targeted otic delivery, addressing a specialized segment of the anti-infective market with limited treatment options.<\/p>\n\n\n\n

Strategic Context<\/h2>\n\n\n\n

For Boji Medical<\/strong>, the transaction aligns with its strategy of developing early-stage pharmaceutical assets and monetizing them through partnerships with specialized commercial-stage companies. As a CRO, this technology transfer represents an opportunity to generate revenue from its internal R&D capabilities beyond traditional contract research services.<\/p>\n\n\n\n

For Chengdu Pusch<\/strong>, the acquisition provides immediate access to a late-preclinical stage asset in the anti-fungal space, potentially accelerating its pipeline development timeline and expanding its portfolio in specialized therapeutic areas.<\/p>\n\n\n\n

External otitis affects millions of patients annually, with fungal etiology accounting for approximately 10% of cases. The targeted ear drop formulation aims to deliver effective therapy directly to the infection site while minimizing systemic exposure and associated side effects.<\/p>\n\n\n\n

Forward-Looking Statements<\/strong>
This brief contains forward-looking statements regarding transaction completion and development timelines. Actual outcomes may differ based on regulatory decisions and market dynamics.-Fineline Info & Tech<\/a><\/p>\n\n\n\n